转染技术市场规模、份额及成长分析（依方法、应用、最终用户及地区划分）－2026-2033年产业预测

预计到 2024 年，转染技术市场规模将达到 13.1 亿美元，到 2025 年将达到 14.4 亿美元，到 2033 年将达到 29.5 亿美元，在预测期（2026-2033 年）内复合年增长率为 9.4%。

慢性疾病的快速增长和人们对个人化医疗日益增长的兴趣正在推动生物製药市场的发展，而转染技术在其研发和生产中发挥关键作用。基因疗法，特别是针对遗传性疾病和癌症的基因疗法的快速发展，凸显了高效病毒载体系统的重要性，从而推动了该领域的需求。持续的研发工作催生了用于转染试剂的创新化学成分和技术，旨在提高疗效并降低细胞毒性。此外，分子和细胞生物学研究的快速发展进一步推动了学术机构、研究实验室和製药公司对转染技术的需求。由于市场竞争依然激烈，各家公司，尤其是在基因治疗领域，正致力于创新、产品差异化和合规性。

转染技术市场驱动因素

在转染技术领域，共转染是一种将多种核酸同时导入真核细胞的重要技术。此技术可将质体DNA、siRNA和多种miRNA组合起来，促进基因表现和调控。其主要目的是将多个外源基因整合到宿主细胞中，从而推动基因治疗和疫苗研发等领域的发展。尤其值得一提的是，该技术利用HEK293等细胞株中的各种质体载体，建构包括慢病毒在内的复杂病毒载体，大大拓展了研究与治疗的可能性。

转染技术市场限制因素

由于各种灭菌方法高成本且操作复杂，转染技术市场面临许多限制因素。这些方法通常需要专用设备和专有组件，导致前期投入和后续维护成本都很高。此外，对专业知识的需求也会进一步阻碍其普及，尤其对于预算有限的学术研究人员和小规模生物技术公司而言更是如此。因此，与这些灭菌技术相关的经济壁垒会限制其在市场上的推广和广泛应用，并给那些希望有效利用这些技术的使用者带来挑战。

转染技术市场趋势

转染技术市场正经历一个显着的趋势，即采用先进的核酸递送系统，包括脂质奈米颗粒、聚合物载体和病毒载体。这一趋势的驱动力在于对更高转染效率、更精准的细胞标靶化和更低细胞毒性的需求，使得这些技术在基因治疗、药物递送和基因组编辑等应用领域极具吸引力。随着生物医学研究的不断深入，人们越来越重视开发安全有效的病毒技术。这反映了业界对临床应用和前沿研究计划中创新解决方案日益增长的需求的积极回应。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析和影响

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 技术进步
• 监管环境
• 价值链分析
• 案例研究分析
• PESTEL 分析
• 总体经济指标
• 市场吸引力指数

全球转染技术市场规模（依产品及复合年增长率划分）（2026-2033 年）

• 成套工具
• 装置

全球转染技术市场规模（依方法及复合年增长率划分）（2026-2033 年）

• 物理转染
  • 电穿孔
  • 基因枪转染/基因枪
  • 显微注射
  • 其他物理转染方法
• 基于生化技术的转染
  • 脂质体
  • 磷酸钙转染
  • 阳离子聚合物转染
  • DEAE-聚葡萄糖转染
  • 磁辅助转染
  • 树状聚合物介导的转染
• 基于病毒载体的转染
• 共转染

全球转染技术市场规模（依应用及复合年增长率划分）（2026-2033 年）

• 生物医学研究
  • 基因和蛋白质表现研究
  • 癌症研究
  • 基因改造模型
• 治疗性药物递送
  • 生物治疗
  • 电免疫疗法
  • 化疗
• 蛋白质生产
• 基于细胞的微阵列。

全球转染技术市场规模（依最终用户划分）及复合年增长率（2026-2033 年）

• 製药和生物技术公司
• 合约研究组织 (CRO) 和合约研发生产力组织 (CDMO)
• 学术研究机构
• 其他的

全球转染技术市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 英国
  • 德国
  • 西班牙
  • 法国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2021-2023年营收年比比较

主要企业简介

• Thermo Fisher Scientific Inc.（US）
• Bio-Rad Laboratories, Inc.（US）
• QIAGEN（Netherlands）
• Merck KGaA（Germany）
• Sartorius AG（Polyplus）（Germany）
• Lonza（Switzerland）
• F. Hoffmann-La Roche Ltd（Switzerland）
• Agilent Technologies, Inc.（US）
• MaxCyte（US）
• Revvity（US）
• Takara Bio Inc.（Japan）
• Promega Corporation（US）
• Danaher Corporation（US）
• BOC Sciences（US）
• RJH BIOSCIENCES（Canada）
• Synvolux（Netherlands）
• Altogen Biosciences（US）
• BioIVT（US）
• Incella GmbH（Germany）
• InvivoGen（France）

结论与建议

Transfection Technologies Market size was valued at USD 1.31 Billion in 2024 and is poised to grow from USD 1.44 Billion in 2025 to USD 2.95 Billion by 2033, growing at a CAGR of 9.4% during the forecast period (2026-2033).

The surging prevalence of chronic diseases and the rising interest in personalized medicine are propelling the biopharmaceuticals market forward, with transfection technologies being pivotal in their development and production. The rapid advancements in gene therapy, particularly for genetic disorders and cancer, underline the necessity for effective viral delivery systems, thus amplifying demand in this sector. Continuous R&D endeavors are yielding innovative chemical formulations for transfection reagents and techniques aimed at enhancing efficacy and reducing cytotoxicity. Furthermore, an upsurge in molecular and cell biology research amplifies the need for transfection technologies across academic institutions, research laboratories, and pharmaceutical companies. As the market remains highly competitive, players are focused on innovation, product differentiation, and compliance with regulatory standards, particularly in gene therapy applications.

Top-down and bottom-up approaches were used to estimate and validate the size of the Transfection Technologies market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Transfection Technologies Market Segments Analysis

Global Transfection Technologies Market is segmented by Product, Method, Application, End User and region. Based on Product, the market is segmented into Kits, Equipment. Based on Method, the market is segmented into Physical transfection (Electroporation, Biolistic transfection/ gene guns, Microinjection, Other physical transfection methods), Biochemical-based transfection (Lipofection, Calcium phosphate transfection, Cationic polymer transfection, DEAE-dextran transfection, Magnet-assisted transfection, Dendrimer-mediated transfection), Viral-vector based transfection, Cotransfection. Based on application, the market is segmented into Biomedical research (Gene and protein expression studies, Cancer research, Transgenic models), Therapeutic delivery (Biotherapeutics, Electroimmunotherapy, Electrochemotherapy), Protein production, Cell-based microarrays. Based on end user, the market is segmented into Pharmaceutical and biotechnology companies, CROs and CDMOs, Academic and research institutes, Other. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Transfection Technologies Market

Co-transfection is a crucial technique in the Transfection Technologies market, allowing for the simultaneous introduction of various nucleic acids into eukaryotic cells. This method supports the use of plasmid DNA alongside combinations of siRNA and multiple miRNAs to facilitate gene expression or regulation. The primary aim is to enable the integration of several foreign genes into a host cell, which can lead to advancements in fields such as gene therapy and vaccine development. Notably, this practice is instrumental in generating complex viral constructs, including lentiviruses, through the utilization of diverse plasmid vectors in cell lines like HEK293, thereby enhancing research and therapeutic possibilities.

Restraints in the Transfection Technologies Market

The Transfection Technologies market faces significant restraints owing to the high costs and complexities associated with various sterilization methods. These methods often require specialized equipment and proprietary components, which can lead to substantial up-front expenses and ongoing maintenance fees. Additionally, the necessity for specialized expertise can further hinder accessibility, particularly for academic researchers and small biotech firms operating on tight budgets. As a result, the economic barriers associated with these sterilization technologies may limit their adoption and availability within the market, creating challenges for those who seek to utilize them effectively.

Market Trends of the Transfection Technologies Market

The Transfection Technologies market is experiencing a significant trend towards the enhanced adoption of advanced delivery systems for nucleic acids, including lipid nanoparticles, polymer-based carriers, and viral vectors. This shift is fueled by the need for improved transfection efficiency, precise cell targeting, and minimized cytotoxicity, thus making these technologies highly attractive for applications in gene therapy, drug delivery, and genome editing. As the biomedical research landscape evolves, there is a heightened focus on developing safe and effective viral technologies, reflecting the industry's response to the increasing demand for innovative solutions in clinical settings and advanced research initiatives.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Driver & Opportunities
  • Restraints & Challenges
• Porters Analysis & Impact
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Technological Advancement
• Regulatory Landscape
• Value Chain Analysis
• Case Study Analysis
• PESTEL Analysis
• Macro-Economic Indicators
• Market Attractiveness Index

Global Transfection Technologies Market Size by Product & CAGR (2026-2033)

• Market Overview
• Kits
• Equipment

Global Transfection Technologies Market Size by Method & CAGR (2026-2033)

• Market Overview
• Physical transfection
  • Electroporation
  • Biolistic transfection/ gene guns
  • Microinjection
  • Other physical transfection methods
• Biochemical-based transfection
  • Lipofection
  • Calcium phosphate transfection
  • Cationic polymer transfection
  • DEAE-dextran transfection
  • Magnet-assisted transfection
  • Dendrimer-mediated transfection
• Viral-vector based transfection
• Cotransfection

Global Transfection Technologies Market Size by Application & CAGR (2026-2033)

• Market Overview
• Biomedical research
  • Gene and protein expression studies
  • Cancer research
  • Transgenic models
• Therapeutic delivery
  • Biotherapeutics
  • Electroimmunotherapy
  • Electrochemotherapy
• Protein production
• Cell-based microarrays.

Global Transfection Technologies Market Size by End User & CAGR (2026-2033)

• Market Overview
• Pharmaceutical and biotechnology companies
• CROs and CDMOs
• Academic and research institutes
• Other

Global Transfection Technologies Market Size & CAGR (2026-2033)

• North America, (Product, Method, Application, End User)
  • US
  • Canada
• Europe, (Product, Method, Application, End User)
  • UK
  • Germany
  • Spain
  • France
  • Italy
  • Rest of Europe
• Asia-Pacific, (Product, Method, Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America, (Product, Method, Application, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa, (Product, Method, Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Thermo Fisher Scientific Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sartorius AG (Polyplus) (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lonza (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MaxCyte (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Revvity (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takara Bio Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Promega Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BOC Sciences (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• RJH BIOSCIENCES (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Synvolux (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Altogen Biosciences (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioIVT (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Incella GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• InvivoGen (France)
  • Conclusio Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendation